Side-by-side · Research reference

5-Amino-1MQvsDSIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft8/38 cited

BHuman-MechanisticDraft8/36 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

01Mechanism of Action

Parameter

5-Amino-1MQ

DSIP

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Feedback intact?

—

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

DSIP

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

100–200 mcg SQ pre-sleepSchneider 1986

Frequency

Once daily, fasted

Once daily, pre-sleep

Lower / starter dose

50 mg / day

50 mcg pre-sleep

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Human-mechanistic + early clinicalSchneider 1986

Duration

8–12 weeks per cycle

Form

Oral capsule

—

Timing

Morning fasted preferred

30–60 min pre-sleep

Half-life

Hours (estimated; no human PK published)

Short plasma; CNS effects last hours

Reconstitution

—

Bacteriostatic water

04Side Effects & Safety

Parameter

5-Amino-1MQ

DSIP

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

Limited modern RCT data

Cancer risk

Unclear — NNMT also studied in oncology contexts

—

Pregnancy / OB

Avoid

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Injection site reaction

—

Mild irritation

Drowsiness

—

Expected effect (intentional)

Vivid dreams

—

Anecdotally reported

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

05Administration Protocol

Parameter

5-Amino-1MQ

DSIP

1. Form

Oral capsule. No injection.

Add 1–2 mL bacteriostatic water to vial.

2. Administration

Take with water, fasted preferred.

SQ — abdomen. Rotate sites.

3. Timing

Morning fasted.

30–60 min pre-sleep.

4. Storage

Room temp ≤25 °C, dry place.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Caveat

Monitor B-vitamin status with chronic use.

29–31G insulin syringe.